Manish Shah, Professor of Medicine and Director of the Gastrointestinal Oncology Program at Weill Cornell Medicine, shared on LinkedIn:
“Find the attached article that highlights our recent CancerCast podcast episode on the breakthrough drug Daraxonrasib (Rasonque) for pancreatic cancer. The article discusses the decades-long challenge it has been to target KRAS, a critical protein that promotes growth, survival, and pancreatic cancer aggressiveness.
Different patients with pancreatic cancer can have different KRAS mutations – Daroxonrasib is the first drug approved to target multiple KRAS mutations. It works in a totally unique way, opening the door for multiple new therapies using the same technology!
Read on, or listen to our podcast on Apple Podcasts, Spotify, YouTube, or the Weill Cornell Medicine website. ”
Other articles featuring Manish Shah on OncoDaily.